Gold prices steady ahead of Fed decision; weekly weakness noted
On Friday, Raymond (NS:RYMD) James expressed a positive outlook on Masimo Corp. (NASDAQ: NASDAQ:{{16565|MAMASI), currently trading at $171.02 with a market capitalization of $9.16 billion, by increasing the company's price target from $170.00 to $194.00. The firm maintained its Outperform rating for the healthcare technology company's shares.
The adjustment comes as Raymond James analysts delve into the potential for Masimo to grow its earnings per share (EPS) at a rate of over 15% in the coming years. The analysts highlighted the company's renewed focus on its core healthcare business as a key factor for this anticipated growth. According to InvestingPro data, the company maintains a healthy gross margin of 50.05% and has demonstrated strong momentum with a 30.05% return over the past six months.
According to Raymond James, Masimo's unique opportunity for margin expansion, coupled with a newly appointed board of directors motivated to enhance profitability, is expected to significantly bolster the company's core earnings power.
The firm's confidence in Masimo's prospects is based on an analysis that suggests the company is well-positioned to achieve sustainable growth. The raised price target reflects this analysis and the anticipated positive impact on Masimo's financial performance.
The statement from Raymond James underscores the belief that, despite the importance of timing in the recognition of this upside, the fundamentals are in place for Masimo to continue its trajectory of financial success. InvestingPro analysis suggests the stock is currently trading slightly above its Fair Value, with 13 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, healthcare companies have been the focus of Piper Sandler analysts ahead of a major investor conference. The analysts anticipate positive fiscal year outlooks for several companies, including ATEC, ATRC, and KIDS. The analysts also see potential upside for consensus numbers for FNA and SIBN, which typically issue full-year guidance with Q4 earnings.
Furthermore, Procept BioRobotics has initiated a public offering of common stock valued at $175 million, with BofA Securities and Morgan Stanley (NYSE:MS) serving as the joint book-running managers. The company reported robust revenue growth of 66% in the third quarter, totaling approximately $58.4 million, largely attributed to the company's Hydros units.
Masimo Corporation has recently experienced significant organizational changes, including the termination of Tao Levy, the company's Executive Vice President of Business Development. The company has also appointed Michelle Brennan as interim Chief Executive Officer for a six-month term. Masimo reported robust growth in its third quarter of 2024, with a year-over-year increase in healthcare revenues and a solid non-GAAP earnings per share growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.